HK1062401A1 - Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances - Google Patents

Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances

Info

Publication number
HK1062401A1
HK1062401A1 HK04104742A HK04104742A HK1062401A1 HK 1062401 A1 HK1062401 A1 HK 1062401A1 HK 04104742 A HK04104742 A HK 04104742A HK 04104742 A HK04104742 A HK 04104742A HK 1062401 A1 HK1062401 A1 HK 1062401A1
Authority
HK
Hong Kong
Prior art keywords
galanthamine
psychotropic
treatment
central nervous
substances
Prior art date
Application number
HK04104742A
Other languages
English (en)
Inventor
Klaus Opitz
Joachim Moormann
Thomas Hille
Frank Becher
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1062401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of HK1062401A1 publication Critical patent/HK1062401A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK04104742A 2001-04-24 2004-07-02 Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances HK1062401A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119862A DE10119862A1 (de) 2001-04-24 2001-04-24 Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
PCT/EP2002/004277 WO2002085370A1 (de) 2001-04-24 2002-04-18 Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (1)

Publication Number Publication Date
HK1062401A1 true HK1062401A1 (en) 2004-11-05

Family

ID=7682409

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104742A HK1062401A1 (en) 2001-04-24 2004-07-02 Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances

Country Status (27)

Country Link
US (1) US8207159B2 (pl)
EP (1) EP1383507B1 (pl)
JP (1) JP2004531533A (pl)
KR (1) KR20040005934A (pl)
CN (1) CN100400043C (pl)
AR (1) AR033468A1 (pl)
AT (1) ATE378052T1 (pl)
AU (1) AU2002308148B2 (pl)
BR (1) BR0209126A (pl)
CA (1) CA2444818C (pl)
CZ (1) CZ20032789A3 (pl)
DE (2) DE10119862A1 (pl)
DK (1) DK1383507T3 (pl)
EA (1) EA200301135A1 (pl)
ES (1) ES2296990T3 (pl)
HK (1) HK1062401A1 (pl)
HU (1) HUP0401123A3 (pl)
IL (2) IL158382A0 (pl)
MX (1) MXPA03009765A (pl)
NO (1) NO20034740L (pl)
NZ (1) NZ529004A (pl)
PL (1) PL207525B1 (pl)
PT (1) PT1383507E (pl)
SK (1) SK287235B6 (pl)
TW (1) TWI329512B (pl)
WO (1) WO2002085370A1 (pl)
ZA (1) ZA200308004B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE487492T1 (de) * 2003-02-27 2010-11-15 Eisai R&D Man Co Ltd Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
FR2930891B1 (fr) 2008-05-06 2010-09-24 Biocodex Composes anti-amnesiants et compositions pharmaceutiques les comprenant
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
EP3297632A4 (en) * 2015-05-18 2019-01-16 Synaptec Development LLC GALANTAMINE ELIMINATION OF AMYLOIDSS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3843239C1 (pl) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5015645A (en) * 1989-10-19 1991-05-14 Ciba-Geigy Corporation Tetracyclic pyrrole lactam derivatives
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
EP1231877A4 (en) * 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders

Also Published As

Publication number Publication date
CA2444818C (en) 2009-06-16
HUP0401123A2 (hu) 2004-09-28
NO20034740D0 (no) 2003-10-23
ES2296990T3 (es) 2008-05-01
MXPA03009765A (es) 2005-04-19
CZ20032789A3 (en) 2004-05-12
AR033468A1 (es) 2003-12-17
ZA200308004B (en) 2004-02-11
WO2002085370A1 (de) 2002-10-31
NO20034740L (no) 2003-10-23
NZ529004A (en) 2007-01-26
EP1383507B1 (de) 2007-11-14
EA200301135A1 (ru) 2004-04-29
CN1505516A (zh) 2004-06-16
SK13152003A3 (sk) 2004-04-06
SK287235B6 (sk) 2010-04-07
IL158382A (en) 2009-09-01
EP1383507A1 (de) 2004-01-28
DK1383507T3 (da) 2008-03-17
HUP0401123A3 (en) 2008-01-28
AU2002308148B2 (en) 2006-11-02
JP2004531533A (ja) 2004-10-14
CN100400043C (zh) 2008-07-09
BR0209126A (pt) 2004-07-27
TWI329512B (en) 2010-09-01
DE50211207D1 (de) 2007-12-27
US20040116406A1 (en) 2004-06-17
CA2444818A1 (en) 2002-10-31
IL158382A0 (en) 2004-05-12
DE10119862A1 (de) 2002-11-07
PT1383507E (pt) 2008-02-20
KR20040005934A (ko) 2004-01-16
PL207525B1 (pl) 2010-12-31
PL366840A1 (pl) 2005-02-07
ATE378052T1 (de) 2007-11-15
US8207159B2 (en) 2012-06-26

Similar Documents

Publication Publication Date Title
GEP20084325B (en) Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
CY1116327T1 (el) Φαρμακευτικη δοσολογικη μορφη περιεχουσα υδροχλωρικη οξυκωδονη εχουσα λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
TW200531680A (en) Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
HK1077808A1 (zh) 四氟芐衍生物及內含同類項目以預防和治療中樞神經系統中急性與慢性神經退化疾病的醫藥成份
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
TW200407305A (en) Novel compounds
MX2007008227A (es) Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
ATE451917T1 (de) Pharmazeutische zubereitung enthaltend einen nmda rezeptor agonisten für die behandlung von bewegungsstörungen
PT1176963E (pt) Utilizacao de ligandos do receptor d3 da dopamina no fabrico de medicamentos para o tratamento de disturbios da funcao renal
CA2176298A1 (en) A single high dose fluoroquinolone treatment
HK1062401A1 (en) Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
HRP20100373T4 (hr) Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima
WO2003094842A3 (en) Conjugates comprising central nervous system active drug
FI3825306T3 (fi) Morfinaaniyhdisteitä
WO2004082584A3 (en) 5ht2c receptor antagonists in the treatment of schizophrenia
MY135676A (en) Use of deoxypeganine for the treatment of pathological manifestations of the central nervous system based on intoxication with psychotropic substances
NO953892L (no) Imidazolokinoksalinon-derivater som EAA-antagonister
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
WO2007015173A3 (en) Inflammation
BR0012758A (pt) Tablete detergente revestido
WO2008038119A3 (en) A composition comprising a coenzyme q10 - cyclodextrin - complex and a carotene and use thereof for the treatment of pathologic states of e.g. the central nervous system
MXPA06013945A (es) Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
RU2002122711A (ru) Способ профилактики вредного воздействия окружающей среды
WO2003063779A3 (en) Selective analgesic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120418